Literature DB >> 9005957

Induction of antigen-specific isotype switching by in vitro immunization of human naive B lymphocytes.

A Zafiropoulos1, E Andersson, E Krambovitis, C A Borrebaeck.   

Abstract

The use of in vitro immunization technology for the generation of human antigen-specific antibodies has essentially resulted in low affinity IgM antibodies, resembling an in vivo primary immune response. We now describe a detailed reproducible protocol for a two-step in vitro immunization, which yields isotype switched, antigen-specific human antibodies. The immunizing antigen was a 30aa synthetic peptide, containing both a B (15aa V3 peptide of the HIV-1) and a T helper cell epitope (15aa peptide from tetanus toxin). The immunization protocol includes: (i) a selection procedure of donors with a memory T cell response against tetanus toxoid; (ii) immunization of mature naive peripheral B lymphocytes in two distinct phases, involving a primary and a secondary step. None of the donors which were examined after primary immunization showed at any time an IgG anti-V3 specific antibody response, while all the donors showed an IgM response. After the secondary immunization step, anti-V3 antibodies of both IgM and IgG isotypes were detected. The switch frequency event was high among the tested donors (5/8).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005957     DOI: 10.1016/s0022-1759(96)00207-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Human antibodies for immunotherapy development generated via a human B cell hybridoma technology.

Authors:  Jian Li; Tao Sai; Marc Berger; Qimin Chao; Diane Davidson; Gaurav Deshmukh; Brian Drozdowski; Wolfgang Ebel; Stephen Harley; Marianne Henry; Sara Jacob; Brad Kline; Ella Lazo; Frank Rotella; Eric Routhier; Kathryn Rudolph; Jeaneen Sage; Paul Simon; Jun Yao; Yuhong Zhou; Mani Kavuru; Tracey Bonfield; Mary Jane Thomassen; Philip M Sass; Nicholas C Nicolaides; Luigi Grasso
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

2.  Long-term immunologically competent human peripheral lymphoid tissue cultures in a 3D bioreactor.

Authors:  Igor Kuzin; Hongliang Sun; Safiekhatoon Moshkani; Changyong Feng; Athanasios Mantalaris; J H David Wu; Andrea Bottaro
Journal:  Biotechnol Bioeng       Date:  2011-02-18       Impact factor: 4.530

3.  The HIV-1 gp120/V3 modifies the response of uninfected CD4 T cells to antigen presentation: mapping of the specific transcriptional signature.

Authors:  Antigone K Morou; Filippos Porichis; Elias Krambovitis; George Sourvinos; Demetrios A Spandidos; Alexandros Zafiropoulos
Journal:  J Transl Med       Date:  2011-09-24       Impact factor: 5.531

4.  Production of antigen-specific human IgGs by in vitro immunization.

Authors:  A Wijkhuisen; A Savatier; N Cordeiro; M Léonetti
Journal:  BMC Biotechnol       Date:  2016-02-24       Impact factor: 2.563

5.  Potentiating Antigen-Specific Antibody Production with Peptides Obtained from In Silico Screening for High-Affinity against MHC-II.

Authors:  Yoshiro Hanyu; Yuto Komeiji; Mieko Kato
Journal:  Molecules       Date:  2019-08-14       Impact factor: 4.411

6.  Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.

Authors:  Li-Te Chin; Chishih Chu; Han-Min Chen; Shu-Ching Hsu; Bor-Chun Weng; Chi-Hong Chu
Journal:  BMC Biotechnol       Date:  2007-08-23       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.